Navigation Links
FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011
Date:8/22/2008

OGX-011 treatment can significantly reduce serum clusterin levels and that achieving low serum clusterin levels during treatment is correlated with improved survival. Furthermore, serum clusterin levels during OGX-011 treatment may be predictive of a treatment benefit with OGX-011. In patients with HRPC who had failed first-line docetaxel while on or within six months of first-line docetaxel therapy and received second-line chemotherapy in combination with OGX-011 (Study OGX-011-07), achieving or maintaining low serum clusterin levels correlated with improved survival. Similar results were seen in Study OGX-011-05 in patients with NSCLC who were treated with gemcitabine plus a platinum regimen and OGX-011. Data from the Phase 2 study in HRPC were presented at the 2008 Annual Meeting of the American Society of Clinical Oncology.

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of specific proteins associated with treatment resistance; OGX-427 and SN2310 are in Phase 1 clinical development; and CSP9222 and OGX-225 are currently in pre-clinical development. More information is available at http://www.oncogenex.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning Fast Track Designation for OGX-011 and anticipated clinical and other product development activities and
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GlaxoSmithKline To Post Quarterly US Grants Report
2. FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
3. FDA Grants Epeius Biotechnologies Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
4. US FDA Grants Pediatric Exclusivity for UCBs Keppra(R)
5. Xceed Molecular Grants Gen-Probe License to Xceeds Flow-Thru Chip(R) Technology for Multiplex Molecular Diagnostics
6. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
7. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
8. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
9. Susan G. Komen for the Cure(R) Announces Largest Grants Slate Ever: $100 Million to Speed Delivery of Breast Cancer Discoveries, Cures
10. European Union, State of Brandenburg, Award Grants to Alcat Europe, GmbH
11. FDA Grants Market Clearance to Aerocrine Inc.s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... -- Baylor Research Institute (BRI) at ... (TGen) in Phoenix, AZ , today ... and treatments for patients with a broad range of cancers. ... new clinical trials and access to technology to drive the ... to bedside across Baylor Scott & White Health,s ...
(Date:5/21/2015)... YORK , May 21, 2015  Prima Biomed ... company that is striving to become a leader in ... cancer, recently announced that the final CVac data from ... shown a clear trend for a clinically meaningful improvement ... in second remission patients. In the group ...
(Date:5/21/2015)... 2015 Patent Offering, The patent’s technology ... or therapeutic imaging within a body lumen (open space). ... having a low cost, single-use disposable illumination and camera ... October 18, 2013 and the patent approval was received ... physician to customize the lighting and magnification of the ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Veolia’s ... an exclusive North American distribution agreement with VWR ... system. , With more than 160 years of ... and services for laboratory and production facilities, has ... excellence and differentiated services to enable science. ...
Breaking Biology Technology:Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4Correction Continues after Big Move - BrokerBank Securities, Inc. 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
... and you haven,t backed up your holiday photos is a step ... into a new kind of computer memory. , Physicists at ... have made new advances in researching a new kind of memory, ... information on home computers. , Your hard drive ...
... companies align to leverage technologies for PACS data disaster ... Management (IKM) business unit of Siemens Healthcare ... and Harris Corporation ( www.harris.com ... providers affordable solutions critical for Picture Archiving and Communication ...
... April 3 Verenium Corporation (Nasdaq: ... high-performance specialty enzymes and next-generation cellulosic ethanol, today ... demonstration-scale facility in Jennings, Louisiana, and the recent ... Verenium is now consolidating its research and development ...
Cached Biology Technology:Beating the back-up blues 2Siemens Healthcare Announces Planned Collaboration with Harris Corporation 2Siemens Healthcare Announces Planned Collaboration with Harris Corporation 3Siemens Healthcare Announces Planned Collaboration with Harris Corporation 4Verenium Announces Organizational Changes 2Verenium Announces Organizational Changes 3
(Date:5/19/2015)... 19, 2015 Research ... addition of the  "Genetic Testing Market Outlook ... http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic Testing ... of the current and future genetic testing ... their working principles and types are covered ...
(Date:5/11/2015)... Calif. , May 11, 2015  Synaptics ... of human interface solutions, today announced the appointment ... President and Chief Financial Officer, reporting to ... replaces Synaptics, current Chief Financial Officer, Kathleen ... 2014. Mr. Ali brings extensive ...
(Date:5/8/2015)... JOSE, Calif. , May 8, 2015 Synaptics ... interface solutions, today announced that members of the executive management ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Waterfront Hotel in Boston, MA ... May 27, 2015 Time: 2:45pm ET Location: The New York ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Synaptics to Present at Upcoming Investor Conferences 2
... a consortium of 98 Ph.D.-granting universities, has selected Holly ... of Delaware,s College of Earth, Ocean, and Environment, to ... The competitive award, which provides $5,000 from ORAU ... university, is intended to enrich the research and educational ...
... scientists discovered a defect in cellular pathways that provides a ... in newborns, known as craniosynostosis. Mutations of the ... events that regulate bone formation at the stem cell level, ... journal Science Signaling . "Our work contributes to ...
... O157:H7 is present but rare in some wildlife species of ... to as the nation,s "salad bowl," reports a team or ... who are nearing completion of a massive field study to ... near Central Coast farms, presented their findings today during the ...
Cached Biology News:University of Delaware professor wins Powe Award from Oak Ridge Associated Universities 2University of Delaware professor wins Powe Award from Oak Ridge Associated Universities 3Stem-cell disruption induces skull deformity, UR study shows 2E. coli 0157:H7 present but not common in wildlife of nation's salad bowl 2E. coli 0157:H7 present but not common in wildlife of nation's salad bowl 3
... CultureWell cell culture chambered coverslips ... cells for staining and imaging. ... silicone gaskets with standard optical-quality ... and ready to use. Preassembled ...
Vybrant® Multidrug Resistance Assay Kit...
... mL - 25 mL pipets ,Angled acrylic pipet ... standard square or round pipet cans. Constructed of 6 ... 76 mm W x 76 mm H x 289 ... Overall dimensions: 89 mm W x 406 mm H ...
...
Biology Products: